Sandoz (OTCQX:SDZNY) Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S.
Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the U.S. Food and Drug Administration for the treatment of certain chronic inflammatory